PMID- 27567246
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20170502
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 40
DP  - 2016 Nov
TI  - Polyclonal IgM and IgA block in vitro complement deposition mediated by 
      anti-ganglioside antibodies in autoimmune neuropathies.
PG  - 11-15
LID - S1567-5769(16)30337-X [pii]
LID - 10.1016/j.intimp.2016.08.019 [doi]
AB  - Intravenous immunoglobulin (IVIG), consisting of IgG, is the first-line treatment 
      for Guillain-Barre syndrome and multifocal motor neuropathy. IgG, but neither IgM 
      nor IgA, has been demonstrated in vitro to inhibit complement deposition mediated 
      by anti-ganglioside autoantibodies in sera from patients with both conditions. 
      The objective of this study is to investigate the in vitro effectiveness of IgM 
      and IgA in inhibiting complement deposition to ganglioside/anti-ganglioside 
      antibody complexes. Serum samples were obtained from patients with multifocal 
      motor neuropathy associated with anti-GM1 IgM antibodies, Guillain-Barre syndrome 
      associated with anti-GM1 IgG antibodies and Miller Fisher syndrome associated 
      with anti-GQ1b IgG antibodies. Inhibition of complement deposition using 
      different immunoglobulin preparations was measured by enzyme-linked immunosorbent 
      assay. IgM/A-enriched IVIG and immunoglobulin isotypes (polyclonal IgM and IgA) 
      showed higher potential in inhibiting complement deposition than standard IVIG. 
      Although the safety concerns about the use of IgM and IgA for an immunotherapy 
      still remain, IgM and IgA may serve as an alternative immunotherapy in those 
      anti-ganglioside antibody-mediated neuropathies.
CI  - Copyright (c) 2016 Elsevier B.V. All rights reserved.
FAU - Sudo, Makoto
AU  - Sudo M
AD  - Department of Medicine Yong Loo Lin, School of Medicine, National University of 
      Singapore, Singapore.
FAU - Miyaji, Kazuki
AU  - Miyaji K
AD  - Department of Medicine Yong Loo Lin, School of Medicine, National University of 
      Singapore, Singapore.
FAU - Spath, Peter J
AU  - Spath PJ
AD  - Institute of Pharmacology, University of Bern, Switzerland.
FAU - Morita-Matsumoto, Kana
AU  - Morita-Matsumoto K
AD  - Structural Glycobiology Team, RIKEN, Japan.
FAU - Yamaguchi, Yoshiki
AU  - Yamaguchi Y
AD  - Structural Glycobiology Team, RIKEN, Japan.
FAU - Yuki, Nobuhiro
AU  - Yuki N
AD  - Department of Medicine Yong Loo Lin, School of Medicine, National University of 
      Singapore, Singapore; Department of Physiology Yong Loo Lin, School of Medicine, 
      National University of Singapore, Singapore. Electronic address: 
      gbs.yuki.cidp@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160824
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (anti-IgG)
RN  - 0 (anti-IgM)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Antibodies, Anti-Idiotypic/blood/immunology
MH  - Complement System Proteins/*immunology
MH  - Guillain-Barre Syndrome/blood/*immunology
MH  - Humans
MH  - Immunoglobulin A/*pharmacology
MH  - Immunoglobulin M/*pharmacology
MH  - Immunoglobulins, Intravenous/*pharmacology
OTO - NOTNLM
OT  - Anti-ganglioside antibody
OT  - Complement
OT  - Guillain-Barre syndrome
OT  - Intravenous immunoglobulin
OT  - Multifocal motor neuropathy
EDAT- 2016/08/28 06:00
MHDA- 2017/05/04 06:00
CRDT- 2016/08/28 06:00
PHST- 2016/05/12 00:00 [received]
PHST- 2016/08/14 00:00 [revised]
PHST- 2016/08/18 00:00 [accepted]
PHST- 2016/08/28 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
PHST- 2016/08/28 06:00 [entrez]
AID - S1567-5769(16)30337-X [pii]
AID - 10.1016/j.intimp.2016.08.019 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2016 Nov;40:11-15. doi: 10.1016/j.intimp.2016.08.019. Epub 
      2016 Aug 24.